BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 53.47

Change

0.00 (0.00)%

Market Cap

USD 5.40B

Volume

0.68M

Analyst Target

USD 83.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
RCUS Arcus Biosciences Inc

-0.98 (-5.52%)

USD 1.44B
NUVB Nuvation Bio Inc

-0.08 (-2.66%)

USD 0.74B
DNA Ginkgo Bioworks Holdings

-0.37 (-4.22%)

USD 0.47B
ANRO Alto Neuroscience, Inc.

-0.34 (-7.02%)

USD 0.37B
ADCT ADC Therapeutics SA

-0.05 (-1.68%)

USD 0.29B
CYBN Cybin Inc

-0.30 (-2.50%)

USD 0.21B
ANVS Annovis Bio Inc

-0.11 (-1.44%)

USD 0.10B
PLX Protalix Biotherapeutics Inc

+0.12 (+10.00%)

USD 0.09B
ARMP Armata Pharmaceuticals Inc

+0.50 (+22.22%)

USD 0.08B
OSTX OS Therapies Incorporated

-0.05 (-1.87%)

USD 0.07B

ETFs Containing BHVN

IBRN iShares Trust - iShares N.. 4.87 % 0.00 %

-0.77 (-2.70%)

USD 4.01M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.93% 45% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.93% 45% F 78% C+
Trailing 12 Months  
Capital Gain 86.96% 52% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.96% 52% F 90% A-
Trailing 5 Years  
Capital Gain 11.61% 62% D 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.61% 62% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 44.77% 84% B 93% A
Dividend Return 44.77% 84% B 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 94.54% 43% F 9% A-
Risk Adjusted Return 47.35% 97% N/A 65% D
Market Capitalization 5.40B 100% F 78% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.